Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
After the transaction, it will be NovaBay’s largest shareholder with 6.6 million shares, 37% of the total.
Nanjing Legend Biotech received a very large $350M upfront payment from Janssen Biotech to partner Legend’s impressively effective CAR-T candidate.
Mallinckrodt picks up Sucampo’s Amitiza as well as two other pipeline compounds.
Arno Therapeutics is calling it quits. It sold off all its assets, with the final asset being the rights to Onapristone, which it sold to Context Biopharma.
Roche got in some last-minute Christmas shopping, shelling out $1.7B for San Diego’s Ignyta.
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.
Takeover whispers boosted long-standing target Shire to the top of the FTSE 100 as the pharma firm’s shares rallied on hopes of a mega deal bringing shareholders an early Christmas present.
Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday.
Ultragenyx CEO Emil Kakkis said the sale of the PRV will provide the company with an “important source of non-dilutive capital” that will be used to advance the company’s pipeline of rare and ultra-rare therapies.